Stem Cell Institute Philippines

novel inductions for the future...

Stem Cell Treatment for Erectile Dysfunction

 

Stem Cell Treatment for Erectile Dysfunction is Available at ASCI

 

 

 

 

 

Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. J Transl Med. 2017 Sep 22;15(1):197 Authors: Centeno C, Markle J, Dodson E, Stemper I, Williams CJ, Hyzy M, Ichim T, Freeman M Abstract BACKGROUND: Degenerative disc disease (DDD) is a common cause of lower back pain with radicular symptoms and has a significant socioeconomic impact given the associated disability. Limited effective conservative therapeutic options result in many turning to surgical alternatives for management, which vary in the rate of success and also carry an increased risk of morbidity and mortality associated with the procedures. Several animal based studies and a few human pilot studies have demonstrated safety and suggest efficacy in the treatment of DDD with mesenchymal stem cells (MSCs). The use of bone marrow-derived MSCs for the treatment of DDD is promising and in the present study we report on the safety and efficacy findings from a registry based proof of concept study using a percutaneous intradiscal injection of cultured MSCs for the management of DDD with associated radicular symptoms. METHODS: Thirty-three patients with lower back pain and disc degeneration with a posterior disc bulge diagnosed on magnetic resonance imaging (MRI) met the inclusion criteria and were treated with culture-expanded, autologous, bone marrow-derived MSCs. Prospective registry data was obtained at multiple time intervals up to 6 years post-treatment. Collected outcomes included numeric pain score (NPS), a modified single assessment numeric evaluation (SANE) rating, functional rating index (FRI), measurement of the intervertebral disc posterior dimension, and adverse events. RESULTS: Three patients reported pain related to procedure that resolved. There were no serious adverse events (i.e. death, infection, or tumor) associated with the procedure. NPS change scores relative to baseline were significant at 3, 36, 48, 60, and 72 months post-treatment. The average modified SANE ratings showed a mean improvement of 60% at 3 years post-treatment. FRI post-treatment change score averages exceeded the minimal clinically important difference at all time points except 12 months. Twenty of the patients treated underwent post-treatment MRI and 85% had a reduction in disc bulge size, with an average reduction size of 23% post-treatment. CONCLUSIONS: Patients treated with autologous cultured MSCs for lower back pain with radicular symptoms in the setting of DDD reported minor adverse events and significant improvements in pain, function, and overall subjective improvement through 6 years of follow-up. NCT03011398. A Clinical Registry of Orthobiologics Procedures. https://clinicaltrials.gov/ct2/show/NCT03011398?term=orthobiologics&rank=1. PMID: 28938891 [PubMed - in process]
Read more...
Immunomodulation of Mesenchymal Stem Cells in discogenic pain. Spine J. 2017 Sep 19;: Authors: Miguélez-Rivera L, Pérez-Castrillo S, González-Fernández ML, Prieto-Fernández JG, López-González ME, García-Cosamalón J, Villar-Suárez V Abstract BACKGROUND CONTEXT: Back pain is a highly prevalent health problem in the world today and has a great economic impact on the healthcare budgets. Intervertebral disc degeneration has been identified as a main cause of back pain. Inflammatory cytokines produced by macrophages or disc cells in an inflammatory environment play an important role in painful progressive degeneration of intervertebral disc. Mesenchymal stem cells (MSCs) have shown to have immunosuppressive and anti-inflammatory properties. MSCs express a variety of chemokines and cytokines receptors having tropism to inflammation sites. PURPOSE: To develop an in vitro controlled and standardized model of inflammation and degeneration of intervertebral disc with rat cells and to evaluate the protective and immunomodulatory effect of conditioned medium from the culture of MSCs to improve the conditions presented in herniated disc and discogenic pain processes. STUDY DESIGN: This is an experimental study. METHODS: In this study, an in vitro model of inflammation and degeneration of intervertebral disc has been developed and the effectiveness of conditioned medium from the culture of MSCs. This study was financially supported by the Fundación Leonesa Proneurociencias that invested 10.000 $ and no conflict of interest is declared. RESULTS: Conditioned medium from MSCs down-regulated the expression of various pro-inflammatory cytokines produced in the pathogenesis of discogenic pain such as IL-1β, IL-6, IL-17 and TNF. CONCLUSIONS: MSCs represent a promising alternative strategy in the treatment of intervertebral disc degeneration inasmuch as there is currently no treatment which leads to a complete remission of long-term pain in the absence of drugs. PMID: 28939169 [PubMed - as supplied by publisher]
Read more...